<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DISEASE CHARACTERISTICS: <z:mp ids='MP_0009563'>Dyskeratosis</z:mp> congenita (DC), a telomere biology disorder, is characterized by a classic triad of <z:hpo ids='HP_0002164'>dysplastic nails</z:hpo>, lacy reticular <z:hpo ids='HP_0001000'>pigmentation</z:hpo> of the upper chest and/or neck, and <z:hpo ids='HP_0002745'>oral leukoplakia</z:hpo>, as well as increased risk of progressive <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> (BMF), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (usually <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> of the head/neck or anogenital <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>), and <z:hpo ids='HP_0002206'>pulmonary fibrosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Other findings can include: <z:hpo ids='HP_0001000'>abnormal pigmentation</z:hpo> changes not restricted to the upper chest and neck, eye abnormalities (<z:hpo ids='HP_0009926'>epiphora</z:hpo>, <z:hpo ids='HP_0000498'>blepharitis</z:hpo>, <z:hpo ids='HP_0000653'>sparse eyelashes</z:hpo>, <z:hpo ids='HP_0000656'>ectropion</z:hpo>, <z:hpo ids='HP_0000621'>entropion</z:hpo>, <z:hpo ids='HP_0001128'>trichiasis</z:hpo>), and <z:hpo ids='HP_0000164'>dental abnormalities</z:hpo> (<z:hpo ids='HP_0000670'>caries</z:hpo>, <z:e sem="disease" ids="C0031090" disease_type="Disease or Syndrome" abbrv="">periodontal disease</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Although most persons with DC have <z:mpath ids='MPATH_458'>normal</z:mpath> psychomotor development and <z:mpath ids='MPATH_458'>normal</z:mpath> neurologic function, significant <z:hpo ids='HP_0001263'>developmental delay</z:hpo> is present in the two variants in which additional findings include <z:hpo ids='HP_0001321'>cerebellar hypoplasia</z:hpo> (Hoyeraal Hreidarsson syndrome) and bilateral <z:hpo ids='HP_0007898'>exudative retinopathy</z:hpo> and <z:hpo ids='HP_0002514'>intracranial calcifications</z:hpo> (<z:e sem="disease" ids="C1327916" disease_type="Disease or Syndrome" abbrv="">Revesz syndrome</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> and progression of manifestations of DC vary: at the mild end of the spectrum are those who have only minimal physical findings with <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow function, and at the severe end are those who have the diagnostic triad and early-<z:hpo ids='HP_0003674'>onset</z:hpo> BMF </plain></SENT>
<SENT sid="4" pm="."><plain>DIAGNOSIS/TESTING: <z:hpo ids='HP_0000001'>All</z:hpo> individuals with DC have abnormally short telomeres for their age, as determined by multicolor flow cytometry fluorescence in situ hybridization (flow-FISH) on white blood cell (WBC) subsets </plain></SENT>
<SENT sid="5" pm="."><plain>To date, six genes, DKC1, TERC, TERT, TINF2 , NHP2, and NOP10, have been found to cause DC </plain></SENT>
<SENT sid="6" pm="."><plain>Mutations in one of these six genes have been identified in approximately half of individuals who meet clinical diagnostic criteria for DC </plain></SENT>
<SENT sid="7" pm="."><plain>Molecular genetic testing is clinically available for <z:hpo ids='HP_0000001'>all</z:hpo> six genes </plain></SENT>
<SENT sid="8" pm="."><plain>MANAGEMENT: Treatment of manifestations: Treatment is tailored to the individual </plain></SENT>
<SENT sid="9" pm="."><plain>Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for BMF and <z:hpo ids='HP_0001909'>leukemia</z:hpo> but historically has had poor long-term efficacy; if a suitable donor is not available, <z:chebi fb="3" ids="50113">androgen</z:chebi> therapy may be considered for BMF </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment of other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> is tailored to the type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Of note, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy may pose an increased risk of prolonged cytopenias, as well as pulmonary and hepatic toxicity </plain></SENT>
<SENT sid="12" pm="."><plain>Treatment of <z:hpo ids='HP_0002206'>pulmonary fibrosis</z:hpo> is primarily supportive, although lung transplantation may be considered on occasion </plain></SENT>
<SENT sid="13" pm="."><plain>Surveillance: For BMF: complete blood count (CBC) annually if <z:mpath ids='MPATH_458'>normal</z:mpath> and more often if abnormal; consider annual bone marrow aspirate and biopsy </plain></SENT>
<SENT sid="14" pm="."><plain>For those on <z:chebi fb="3" ids="50113">androgen</z:chebi> therapy: routine monitoring liver function </plain></SENT>
<SENT sid="15" pm="."><plain>For <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk: monthly self-examination for oral, head, and <z:e sem="disease" ids="C0746787" disease_type="Neoplastic Process" abbrv="">neck cancer</z:e>; annual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening by an otolaryngologist and dermatologist; annual gynecologic examination </plain></SENT>
<SENT sid="16" pm="."><plain>For <z:hpo ids='HP_0002206'>pulmonary fibrosis</z:hpo>: annual pulmonary function tests starting either at diagnosis or when the patient can perform the test (often around age eight years) </plain></SENT>
<SENT sid="17" pm="."><plain>Routine dental screening every six months and good oral hygiene </plain></SENT>
<SENT sid="18" pm="."><plain>Agents/circumstances to avoid: blood donation by family members if HSCT is being considered; non-leukodepleted and non-irradiated blood products; the combination of <z:chebi fb="5" ids="50113">androgens</z:chebi> and G-CSF in treatment of BMF (has been associated with splenic rupture); toxic agents implicated in <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, e.g., smoking </plain></SENT>
<SENT sid="19" pm="."><plain>Testing of relatives at risk: If a relative has signs or symptoms suggestive of DC or is being evaluated as a potential HSCT donor, telomere length testing is warranted or molecular genetic testing if the disease-causing mutation(s) in the family is (are) known </plain></SENT>
<SENT sid="20" pm="."><plain>GENETIC COUNSELING: The <z:hpo ids='HP_0000005'>mode of inheritance</z:hpo> of DC varies by gene: DKC1 (<z:hpo ids='HP_0001417'>X-linked</z:hpo>), TERC and TINF2 (<z:hpo ids='HP_0000006'>autosomal dominant</z:hpo>), TERT (<z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> or <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo>), NHP2 (NOLA2) and NOP10 (NOLA3) (<z:hpo ids='HP_0000007'>autosomal recessive</z:hpo>) </plain></SENT>
<SENT sid="21" pm="."><plain>Genetic counseling regarding risk to family members depends on accurate diagnosis, determination of the <z:hpo ids='HP_0000005'>mode of inheritance</z:hpo> in each family, and results of molecular genetic testing </plain></SENT>
<SENT sid="22" pm="."><plain>Prenatal testing for pregnancies at increased risk is possible for DC if the disease-causing mutation(s) in the family is/are known </plain></SENT>
</text></document>